ICU Medical, Inc. Announces Third Quarter 2016 Results

November 9, 2016

SAN CLEMENTE, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy, oncology and critical care applications, today announced financial results for the third quarter ended September 30, 2016.

Third Quarter 2016 Results

Third quarter 2016 revenue was $97.1 million, compared to $86.0 million in the same period last year. GAAP net income for the third quarter of 2016 was $18.8 million, or $1.09 per diluted share, as compared to GAAP net income of $16.3 million, or $0.98 per diluted share, for the third quarter of 2015.  Adjusted diluted earnings per share for the third quarter of 2016 were $1.35 as compared to $1.00 for the third quarter of 2015. Also, adjusted EBITDA was $34.0 million for the third quarter of 2016 as compared to $29.7 million for the third quarter of 2015.

Vivek Jain, ICU Medical's Chief Executive Officer, said, "We are pleased with our revenue, adjusted EBITDA and net income results in the third quarter driven by strong performance in our Direct channel.  Our recently announced definitive agreement to acquire the Hospira infusion systems business is progressing as anticipated and we continue to expect to close in the first quarter of 2017."

Revenues by market segment for the three months ended September 30, 2016 and 2015 were as follows:

  (dollars in millions)
  Three months ended
September 30, 2016
 Three months ended
September 30, 2015
Market Segment Direct OEM Total Direct OEM Total Total
Infusion Therapy $  45.0  $  22.6  $  67.6  $  33.3  $  29.0  $  62.3  $  5.3 
Oncology    10.8     4.4     15.2     7.6     3.4     11.0     4.2 
Critical Care        14.0     -      14.0     12.5     -      12.5     1.5 
Other    0.2     0.1     0.3     0.2     -      0.2     0.1 
        $  70.0  $  27.1  $  97.1  $  53.6  $  32.4  $  86.0  $  11.1 

The Company ended the third quarter of 2016 with a strong balance sheet. As of September 30, 2016, cash, cash equivalents and short and long-term investment securities totaled $429.6 million and working capital was $470.5 million.  Additionally, the Company generated operating cash flow of $27 million for the third quarter of 2016.

Fiscal Year 2016 Guidance Update

For the year, the Company is updating guidance and now expects its revenue to be in the range of $375 million to $380 million, adjusted diluted earnings per share to be in the range of $4.80 to $4.90 and adjusted EBITDA to be in the range of $132 million to $134 million.

Conference Call

The Company will host a conference call to discuss third quarter 2016 financial results today at 4:30 p.m. EST (1:30 p.m. PST).   The call can be accessed at (800) 936-9761, international (408) 774-4587, conference ID 2992544. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's website at, clicking on the Investors tab, clicking on the Webcast icon and following the prompts. The webcast will also be available by replay.

About ICU Medical, Inc.

About ICU Medical, Inc. (Nasdaq:ICUI) develops, manufactures and sells innovative medical devices used in vascular therapy, oncology and critical care applications. ICU Medical's products improve patient outcomes by helping prevent bloodstream infections and protecting healthcare workers from exposure to infectious diseases or hazardous drugs. The company's complete product line includes custom IV systems, closed delivery systems for hazardous drugs, needlefree IV connectors, catheters and cardiac monitoring systems. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical, Inc. can be found at

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as ''will,'' ''expect,'' ''believe,'' ''could,'' ''would,'' ''estimate,'' ''continue,'' ''build,'' ''expand'' or the negative thereof or comparable terminology, and may include (without limitation) information regarding the Company's expectations, goals or intentions regarding the future, including our full year 2016 guidance and our pending acquisition of the Hospira infusion systems business. These forward-looking statements are based on management's current expectations, estimates, forecasts and projections about the Company and assumptions management believes are reasonable, all of which are subject to risks and uncertainties that could cause actual results and events to differ materially from those stated in the forward-looking statements. These risks and uncertainties include, but are not limited to, decreased demand for the Company's products, decreased free cash flow, the inability to recapture conversion delays or part/resource shortages on anticipated timing, or at all, changes in product mix, increased competition from competitors, lack of continued growth or improving efficiencies, unexpected changes in the Company's arrangements with its largest customers and the Company's ability to meet expectations regarding the timing, completion and integration of the Hospira infusion systems business. Future results are subject to risks and uncertainties, including the risk factors, and other risks and uncertainties, described in the Company's filings with the Securities and Exchange Commission, which include those in the Annual Report on Form 10-K for the year ended December 31, 2015 and our subsequent filings. Forward-looking statements contained in this press release are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

(In thousands)
 September 30,
 December 31,
Cash and cash equivalents$  322,963  $   336,164 
Short-term investment securities   49,475      41,233 
Cash, cash equivalents and investment securities   372,438      377,397 
Accounts receivable, net   53,638      57,847 
Inventories   50,953      43,632 
Prepaid income taxes   15,202      14,366 
Prepaid expenses and other current assets   6,569      7,631 
Assets held for sale   4,249      4,134 
TOTAL CURRENT ASSETS   503,049      505,007 
PROPERTY AND EQUIPMENT, net   80,588      74,320 
GOODWILL   5,577      6,463 
INTANGIBLE ASSETS, net   22,832      23,936 
DEFERRED INCOME TAXES   19,491      17,099 
TOTAL ASSETS$  688,699  $   626,825 
Accounts payable$  12,555  $   13,670 
Accrued liabilities   19,961      28,948 
TOTAL CURRENT LIABILITIES   32,516      42,618 
LONG-TERM LIABILITIES   1,197      1,476 
DEFERRED INCOME TAXES   5,022      1,372 
INCOME TAX LIABILITY   1,488      1,488 
Convertible preferred stock   -       -  
Common stock   1,631      1,608 
Additional paid-in capital   157,603      145,125 
Retained earnings   507,468      453,896 
Accumulated other comprehensive loss   (18,226)     (20,758
TOTAL STOCKHOLDERS' EQUITY   648,476      579,871 
(1) December 31, 2015 balances were derived from audited consolidated financial statements.


(In thousands, except per share data)
 Three Months Ended
September 30,
 Nine Months Ended
September 30,
  2016   2015   2016   2015 
Net sales$  97,098  $  85,891  $  283,659  $  250,876 
Other   10     125     25     405 
TOTAL REVENUE   97,108     86,016     283,684     251,281 
COST OF GOODS SOLD   45,835     39,751     133,046     118,741 
GROSS PROFIT   51,273     46,265     150,638     132,540 
Selling, general and administrative   22,362     20,206     66,828     60,698 
Research and development   3,650     4,227     10,301     11,657 
Restructuring and strategic transaction   2,806     3,411     4,339     3,411 
Gain on sale of building   -      (1,086)    -      (1,086)
Legal settlement   -      (5,261)    -      1,798 
TOTAL OPERATING EXPENSES   28,818     21,497     81,468     76,478 
INCOME FROM OPERATIONS   22,455     24,768     69,170     56,062 
BARGAIN PURCHASE GAIN   346     -      1,456     -  
OTHER INCOME, net   225     230     449     996 
INCOME BEFORE INCOME TAXES   23,026     24,998     71,075     57,058 
PROVISION FOR INCOME TAXES   (4,220)    (8,732)    (17,503)    (17,536)
NET INCOME$  18,806  $  16,266  $  53,572  $  39,522 
Basic$  1.16  $  1.02  $  3.32  $  2.50 
Diluted$  1.09  $  0.98  $  3.13  $  2.41 
Basic   16,200   15,894     16,113   15,790 
Diluted   17,286   16,575     17,100   16,409 

(In thousands)
 Nine months ended
September 30,
  2016   2015 
Net income$  53,572  $  39,522 
Adjustments to reconcile net income to net cash provided by operating activities:   
Depreciation and amortization   14,351     13,266 
Provision for doubtful accounts   -      53 
Provision for warranty and returns   (22)    38 
Stock compensation   11,464     9,305 
Loss (gain) on disposal of property and equipment   40     (1,102)
Bargain purchase gain   (1,456)    -  
Bond premium amortization   1,026     1,451 
Other   69     -  
Changes in operating assets and liabilities:   
Accounts receivable   4,736     (11,390)
Inventories   (6,635)    (4,867)
Prepaid expenses and other assets   (2,228)    (8,824)
Accounts payable   (1,587)    3,246 
Accrued liabilities   (7,314)    6,915 
Income taxes, including excess tax benefits and deferred income taxes   2,691     1,017 
Net cash provided by operating activities   68,707     48,630 
Purchases of property and equipment   (15,018)    (7,729)
Proceeds from sale of assets   1     3,592 
Business acquisitions, net of acquired cash   (2,584)    -  
Intangible asset additions   (861)    (778)
Purchases of investment securities   (111,575)    (40,217)
Proceeds from sale of investment securities   45,429     70,293 
Net cash (used in) provided by investing activities   (84,608)    25,161 
Proceeds from exercise of stock options   15,830     10,974 
Proceeds from employee stock purchase plan   2,361     2,162 
Purchase of treasury stock   (17,155)    (1,523)
Net cash provided by financing activities   1,036     11,613 
Effect of exchange rate changes on cash   1,664     (5,848)
CASH AND CASH EQUIVALENTS, beginning of period   336,164     275,812 
CASH AND CASH EQUIVALENTS, end of period$  322,963  $  355,368 

Use of Non-GAAP Financial Information

This press release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP").  The non-GAAP financial measures should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.  There are material limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be comparable to similarly titled non-GAAP financial measures used by other companies, including peer companies.  Our management believes that the non-GAAP data provides useful supplemental information to management and investors regarding our performance and facilitates a more meaningful comparison of results of operations between current and prior periods.  We use non-GAAP financial measures in addition to and in conjunction with GAAP financial measures to analyze and assess the overall performance of our business, in making financial, operating and planning decisions, and in determining executive incentive compensation.  The non-GAAP financial measures included in this press release are adjusted EBITDA and adjusted diluted earnings per share ("Adjusted Diluted EPS"). 

Adjusted EBITDA excludes the following items:

Intangible asset amortization expense:  We do not acquire businesses or capitalize certain patent costs on a predictable cycle.  The amount of purchase price allocated to intangible assets and the term of amortization can vary significantly and are unique to each acquisition.  Capitalized patent costs can vary significantly based on our current level of development activities.  We believe that excluding amortization of intangible assets provides the users of our financial statements with a consistent basis for comparison across accounting periods.

Depreciation expense:  We exclude depreciation expense in deriving adjusted EBITDA because companies utilize productive assets of different ages and the depreciable lives can vary significantly resulting in considerable variability in depreciation expense among companies.

Stock compensation expense:  Stock-based compensation is generally fixed at the time the stock-based instrument is granted and amortized over a period of several years.  The value of stock options is determined using a complex formula that incorporates factors, such as market volatility, that are beyond our control.  The value of our restricted stock awards is determined using the grant date stock price, which may not be indicative of our operational performance over the expense period.  Additionally, in order to establish the fair value of performance-based stock awards, which are currently an element of our ongoing stock-based compensation, we are required to apply judgment to estimate the probability of the extent to which performance objectives will be achieved.  Based on the above factors, we believe it is useful to exclude stock-based compensation in order to better understand our operating performance.

Restructuring and strategic transaction:  We incur restructuring and strategic transaction charges that result from events, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our ongoing business.  Although these events are reflected in our GAAP financial statements, these unique transactions may limit the comparability of our ongoing operations with prior and future periods.

Gain on sale of building:  Occasionally, we may sell certain assets if no longer needed for current operations.  We exclude any gains or losses recognized on the sale of these assets in determining our non-GAAP financial measures as they may limit the comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance.

Legal settlement:  We may incur charges or benefits as well as legal costs related to litigation and other contingencies.  We exclude these charges or benefits, when significant as well as the legal costs associated with significant legal matters, because we do not believe they are an indication of our operating performance.

Bargain purchase gain:  We may incur a bargain purchase gain on certain acquisitions if the fair market value of the identifiable assets acquired and liabilities assumed, net of deferred taxes exceeds the total consideration paid.  We exclude such gains as they are related to acquisitions and have no direct correlation to the operation of our ongoing business.  

Adjusted Diluted EPS excludes, net of tax, intangible asset amortization expense, stock compensation expense, restructuring and strategic transaction, gain on sale of building, legal settlement and bargain purchase gain, which was tax free.  We apply our GAAP consolidated effective tax rate to our non-GAAP financial measures, other than when the underlying item has a materially different tax treatment.

From time to time in the future, there may be other items that we may exclude if we believe that doing so is consistent with the goal of providing useful information to investors and management.

The following tables reconcile our GAAP and non-GAAP financial measures:

Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)
(In thousands, except per share data)
 Three months ended
September 30,
 Nine months ended
September 30,
  2016   2015   2016   2015 
GAAP net income$  18,806  $  16,266  $  53,572  $  39,522 
Non-GAAP adjustments:       
Stock compensation expense   3,790     3,358     11,464     9,305 
Depreciation and amortization expense   4,703     4,240     14,351     13,266 
Restructuring and strategic transaction   2,806     3,411     4,339     3,411 
Gain on sale of building     (1,086)    -      (1,086)
Legal settlement   -      (5,261)    -      1,798 
Bargain purchase gain   (346)    -      (1,456)    -  
Provision for income taxes   4,220     8,732     17,503     17,536 
Total non-GAAP adjustments   15,173     13,394     46,201     44,230 
Adjusted EBITDA$  33,979  $  29,660  $  99,773  $  83,752 
   Adjusted diluted earnings per share 
 Three months ended
September 30,
 Nine months ended
September 30,
  2016   2015   2016   2015 
GAAP diluted earnings per share$  1.09  $  0.98  $  3.13  $  2.41 
Non-GAAP adjustments:       
Stock compensation expense$  0.22  $  0.20  $  0.67  $  0.57 
Amortization expense$  0.04  $  0.02  $  0.12  $  0.09 
Restructuring and strategic transaction$  0.16  $  0.21  $  0.25  $  0.21 
Gain on sale of building$  -   $  (0.07) $  -   $  (0.07)
Legal settlement$  -   $  (0.32) $  -   $  0.11 
Bargain purchase gain$  (0.02) $  -   $  (0.09) $  -  
Estimated income tax impact from adjustments$  (0.14) $  (0.02) $  (0.36) $  (0.31)
Adjusted diluted earnings per share$  1.35  $  1.00  $  3.72  $  3.01 

Reconciliation of GAAP to Non-GAAP Financial Measures - Fiscal Year 2016 Outlook (Unaudited)
(In millions, except per share data)
 Low End of
 High End of
GAAP net income$  69  $  70 
Non-GAAP adjustments:   
Stock compensation expense   15     15 
Depreciation and amortization expense   19     19 
Restructuring and strategic transaction   7     7 
Bargain purchase gain   (2)    (2)
Provision for income taxes   24     25 
Total non-GAAP adjustments   63     64 
Adjusted EBITDA$  132  $  134 
GAAP diluted earnings per share$  3.96  $  4.06 
Non-GAAP adjustments:   
Stock compensation expense$  0.87  $  0.87 
Amortization expense$  0.16  $  0.16 
Restructuring and strategic transaction$  0.38  $  0.38 
Bargain purchase gain$  (0.09) $  (0.09)
Estimated income tax impact from adjustments$  (0.48) $  (0.48)
Adjusted diluted earnings per share$  4.80  $  4.90 
ICU Medical, Inc.
Scott Lamb, Chief Financial Officer
(949) 366-2183

ICR, Inc.
John Mills, Partner
(646) 277-1254